HRP20000609B1 - Process for the synthesis of hiv protease inhibitors - Google Patents

Process for the synthesis of hiv protease inhibitors

Info

Publication number
HRP20000609B1
HRP20000609B1 HR20000609A HRP20000609A HRP20000609B1 HR P20000609 B1 HRP20000609 B1 HR P20000609B1 HR 20000609 A HR20000609 A HR 20000609A HR P20000609 A HRP20000609 A HR P20000609A HR P20000609 B1 HRP20000609 B1 HR P20000609B1
Authority
HR
Croatia
Prior art keywords
compound
reacting
synthesis
protease inhibitors
hiv protease
Prior art date
Application number
HR20000609A
Other languages
English (en)
Inventor
Al-Farhan Emile
D. Deininger David
Mcghie Stephen
O'callaghan John
Stuart Robertson Mark
Rodgers Keith
Rout Stephen
Singh Hardev
Dennis Tung Roger
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20000609A2 publication Critical patent/HRP20000609A2/hr
Publication of HRP20000609B1 publication Critical patent/HRP20000609B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Postupak za dobivanje spoja formule (I) naznačen time, što sadrži: i) reakciju p-nitrofenilsulfonilskupine sa spojem formule (A) gdje P je amino-zaštitna skupina; ii) uklanjanje zaštite sa spoja dobivenog u koraku i); iii) reakciju spoja dobivenog u koraku ii) sa tetrahidrofuriloksi karbonil skupinom; ili reakciju spoja dobivenog u koraku ii) sa fosgenom, ili ekvivalentom, i reakciju dobivenog međuprodukta sa (S)-tetrahidro-3-furanolom; iiv) redukciju spoja dobivenog u koraku iii), da nastane spoj formule (I). Patent sadrži još 11 patentnih zahtjeva.
HR20000609A 1998-03-20 2000-09-15 Process for the synthesis of hiv protease inhibitors HRP20000609B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors
PCT/GB1999/000852 WO1999048885A1 (en) 1998-03-20 1999-03-18 Process for the synthesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
HRP20000609A2 HRP20000609A2 (en) 2001-04-30
HRP20000609B1 true HRP20000609B1 (en) 2006-05-31

Family

ID=10828884

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000609A HRP20000609B1 (en) 1998-03-20 2000-09-15 Process for the synthesis of hiv protease inhibitors

Country Status (32)

Country Link
US (1) US6281367B1 (hr)
EP (1) EP1066276B1 (hr)
JP (1) JP3363439B2 (hr)
KR (1) KR100555278B1 (hr)
CN (1) CN1308319C (hr)
AP (1) AP1226A (hr)
AT (1) ATE242772T1 (hr)
AU (1) AU751534B2 (hr)
BR (1) BR9908970A (hr)
CA (1) CA2324217C (hr)
CZ (1) CZ299193B6 (hr)
DE (1) DE69908761T2 (hr)
DK (1) DK1066276T3 (hr)
EA (1) EA003022B1 (hr)
EE (1) EE04750B1 (hr)
ES (1) ES2203090T3 (hr)
GB (1) GB9805898D0 (hr)
HK (1) HK1032047A1 (hr)
HR (1) HRP20000609B1 (hr)
HU (1) HUP0105439A3 (hr)
ID (1) ID26587A (hr)
IL (1) IL138127A (hr)
IS (1) IS2273B (hr)
NO (1) NO317648B1 (hr)
NZ (1) NZ506563A (hr)
PL (1) PL201810B1 (hr)
PT (1) PT1066276E (hr)
RS (1) RS49954B (hr)
SK (1) SK283939B6 (hr)
TR (1) TR200002698T2 (hr)
WO (1) WO1999048885A1 (hr)
ZA (1) ZA200004482B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
EP1244610B1 (en) * 1999-12-23 2008-07-16 Ampac Fine Chemicals LLC Improved preparation of 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
DK2767539T3 (en) * 2002-05-16 2017-09-11 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
US7772411B2 (en) 2003-12-23 2010-08-10 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備(3r,3as,6ar)-六氫呋喃并〔2,3-b〕呋喃-3-基(1s,2r)-3-〔〔(4-胺基苯基)磺醯基〕(異丁基)胺基〕-1-苯甲基-2-羥基丙基胺基甲酸酯之方法
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
EP2614055A2 (en) 2010-09-10 2013-07-17 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
ES2123065T3 (es) * 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease

Also Published As

Publication number Publication date
HUP0105439A2 (en) 2002-06-29
CZ299193B6 (cs) 2008-05-14
GB9805898D0 (en) 1998-05-13
EA200000859A1 (ru) 2001-04-23
SK13732000A3 (sk) 2001-08-06
EP1066276A1 (en) 2001-01-10
CZ20003457A3 (cs) 2001-04-11
IS2273B (is) 2007-07-15
ATE242772T1 (de) 2003-06-15
NZ506563A (en) 2003-05-30
CA2324217C (en) 2008-02-19
EE04750B1 (et) 2006-12-15
IL138127A (en) 2003-10-31
TR200002698T2 (tr) 2000-12-21
WO1999048885A1 (en) 1999-09-30
NO20004664L (no) 2000-09-19
KR100555278B1 (ko) 2006-03-03
AU2947599A (en) 1999-10-18
IS5605A (is) 2000-08-29
ES2203090T3 (es) 2004-04-01
PT1066276E (pt) 2003-10-31
EE200000568A (et) 2002-02-15
ID26587A (id) 2001-01-18
HRP20000609A2 (en) 2001-04-30
CN1308319C (zh) 2007-04-04
PL201810B1 (pl) 2009-05-29
JP2002507609A (ja) 2002-03-12
ZA200004482B (en) 2001-11-28
NO317648B1 (no) 2004-11-29
CN1293668A (zh) 2001-05-02
DE69908761D1 (de) 2003-07-17
EP1066276B1 (en) 2003-06-11
US6281367B1 (en) 2001-08-28
DE69908761T2 (de) 2004-02-19
CA2324217A1 (en) 1999-09-30
YU55900A (sh) 2003-02-28
NO20004664D0 (no) 2000-09-19
HK1032047A1 (en) 2001-07-06
PL342602A1 (en) 2001-06-18
AP2000001911A0 (en) 2000-09-30
EA003022B1 (ru) 2002-12-26
JP3363439B2 (ja) 2003-01-08
AP1226A (en) 2003-11-21
SK283939B6 (sk) 2004-05-04
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
DK1066276T3 (da) 2003-10-06
RS49954B (sr) 2008-09-29
AU751534B2 (en) 2002-08-22
BR9908970A (pt) 2000-11-28
KR20010042022A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
AP2002002637A0 (en) Novel piperazine
NO992617D0 (no) Sulfinsyrederivater, deres fremstilling og anvendelse
TW349940B (en) Phenylacetic acid derivatives, processes for their preparation, and their uses as fungicides and pesticides
NO20034291D0 (no) 2-aminopropanolderivater
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
RS65604A (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
YU94103A (sh) Novi derivati sulfonske kiseline
SE9802206D0 (sv) Novel compounds
ATE368645T1 (de) Aminosäurederivate als hiv-protease-inhibitoren
HRP20000609B1 (en) Process for the synthesis of hiv protease inhibitors
ATE341541T1 (de) Synthese von 3,6-dialkyl-5,6-dihydro-4-hydroxy- pyran-2-one
MXPA03009548A (es) Arilsulfonamidas como agentes antivirales.
BR9408392A (pt) Derivados de ácidos arilacéticos e sua utilização como fungicidas
ATE239716T1 (de) Synthese von 3,6-dialkyl-5,6-dihydro-4-hydroxy-2h-pyran-2-on
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
HRP20010798B1 (hr) Postupci priprave pesticidnih međuprodukata
TR199800210T2 (xx) Didepsipeptid temelli endoparazitisid kompozisyonlar, yeni didepsipeptidler ve bunlar�n �retimi i�in i�lemler.
HUP0000726A2 (hu) Eljárás flukonazol előállítására
IT1251202B (it) 6-amminochinoloni, sintesi ed impiego come antibatterici
ES2128031T3 (es) Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.
PT1194398E (pt) Sintese de aminocarnitina (s) e (r) e dos seus derivados, a partir de acido aspartico l e d
HRP940443B1 (en) Process for the preparation of 1-nitro-2,2-diaminoethylene derivatives
PT1296983E (pt) Novo processo para a preparacao de pirazolopirimidinonas
MXPA03003466A (es) Derivados de piranosido.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081230

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20100319